Forest hits setback on new COPD drug, one of its key hopes for sales growth

Forest Laboratories ($FRX) will have to wait for that hoped-for revenue from its new combo LAMA/LABA chronic obstructive pulmonary disease (COPD) therapy--and it may have a tougher time building sales when the time comes. Forest and partner Almirall say they've decided to put off their application for FDA approval for a combination of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting beta agonist. The delay could interfere with their plans to compete against rival drugs that could get to market first. Report